222 related articles for article (PubMed ID: 19783548)
21. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
22. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
[TBL] [Abstract][Full Text] [Related]
23. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
24. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3.
Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO
Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348
[TBL] [Abstract][Full Text] [Related]
25. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
26. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
[TBL] [Abstract][Full Text] [Related]
27. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila).
Kim YT; Shin SM; Lee WY; Kim GM; Jin DK
Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515
[TBL] [Abstract][Full Text] [Related]
28. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
29. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism.
Warrick JM; Morabito LM; Bilen J; Gordesky-Gold B; Faust LZ; Paulson HL; Bonini NM
Mol Cell; 2005 Apr; 18(1):37-48. PubMed ID: 15808507
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.
Evert BO; Vogt IR; Kindermann C; Ozimek L; de Vos RA; Brunt ER; Schmitt I; Klockgether T; Wüllner U
J Neurosci; 2001 Aug; 21(15):5389-96. PubMed ID: 11466410
[TBL] [Abstract][Full Text] [Related]
31. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
32. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
33. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
34. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model.
Cushman-Nick M; Bonini NM; Shorter J
PLoS Genet; 2013; 9(9):e1003781. PubMed ID: 24039611
[TBL] [Abstract][Full Text] [Related]
35. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
36. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
37. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
[TBL] [Abstract][Full Text] [Related]
39. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease.
Chang WH; Tien CL; Chen TJ; Nukina N; Hsieh M
Neurosci Lett; 2009 Apr; 454(2):152-6. PubMed ID: 19429074
[TBL] [Abstract][Full Text] [Related]
40. Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Blount JR; Libohova K; Ranxhi B; Paulson HL; Tsou WL; Todi SV
Neurobiol Dis; 2019 Dec; 132():104535. PubMed ID: 31310802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
